Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target-Reference-Cited by-同舟云学术

Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target

Published:2023-12 Issue: Volume:2 Page:100023
ISSN:2949-6888
Container-title:Aspects of Molecular Medicine
language:en
Short-container-title:Aspects of Molecular Medicine

Author:

Quattrocchi Alberto^ORCID,Cappelli Luca Vincenzo^ORCID,De Simone Giovanna^ORCID,De Marinis Elisabetta,Gentile Martina^ORCID,Gasperi Tecla^ORCID,Pulsoni Alessandro^ORCID,Ascenzi Paolo,Nervi Clara^ORCID

Funder

University of Rome La Sapienza

Ministero dell'Università e della Ricerca

Government of Italy Commission for the Selection of Excellence University Departments

Ministero dell’Istruzione, dell’Università e della Ricerca

Publisher

Elsevier BV

Reference238 articles.

1. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia;Advani;Leuk. Res.,2010

2. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis;Ageberg;Genes Chromosomes Cancer,2008

3. HNRNPA2B1 is a mediator of m(6)a-dependent nuclear RNA processing events;Alarcón;Cell,2015

4. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia;Aldoss;Haematologica,2018

5. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis;Alvarez-Dominguez;Blood,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear miRNAs: Gene Regulation Activities;International Journal of Molecular Sciences;2024-05-31